Rifabutin NDC 70518-4254

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4254Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4254Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4254-0	70518425400	60 CAPSULE in 1 BOTTLE, PLASTIC (70518-4254-0)Marketed from Jan 13, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rifabutin
Generic name (nonproprietary): rifabutin
Active ingredients: Rifabutin — 150 mg/1
Dosage form: Capsule
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 050689
Marketing start: Jan 13, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Rifamycins (Chemical structure)
Identifiers: Product ID 70518-4254_5a6f9607-503d-bcb7-e063-6394a90a67c6SPL ID 5a6f9607-503d-bcb7-e063-6394a90a67c6SPL set ID 25a60937-cbbe-4a50-994f-2ce15203f589RxCUI 198200UNII 1W306TDA6S
Pharmacologic class: Rifamycin Antimycobacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518425400 followed by a unit qualifier and the quantity

Package 70518-4254-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 1, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Rifabutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 050689

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 050689
Product	Strength	Form · route	Labeler	Product NDC
Rifabutin	Rifabutin 150 mg/1	CapsuleOral	Mylan Pharmaceuticals Inc.	59762-1350